Enliven Therapeutics Inc · Q4 2021 earnings

Briefing

Imara Inc. reported financial results for the year ended December 31, 2021, and reviewed recent business highlights.

Imara Inc. reported its full year 2021 financial results, highlighting the completion of enrollment in Phase 2b programs and the addition of a clinical indication in heart failure with preserved ejection fraction (HFpEF) for tovinontrine, along with the expansion of their pipeline to include IMR-261. The company's cash, cash equivalents and investments totaled $90.3 million. They anticipate that the cash will be sufficient to fund operations substantially through the first quarter of 2023.

• Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022
• Changed primary endpoint of Ardent Phase 2b trial in sickle cell disease to reductions in annualized rate of VOCs at written request of the FDA
• Added clinical indication for tovinontrine to include the treatment of HFpEF; anticipate first subject dosing in Phase 2 trial in second quarter of 2022
• Expanded pipeline with addition of IMR-261, an oral, clinic-ready Nrf2 activator with potential indications in hemoglobin and iron overload disorders

Headline financials

Revenue & EPS history

Imara anticipates research and development expenses between $60 million and $65 million, and general and administrative expenses between $13 million and $15 million for the full year 2022. They believe cash, cash equivalents and investments will be sufficient to fund operations substantially through the first quarter of 2023.